YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Isolation and Properties of Cytotoxic Antibiotics Produced by Myxococcus stipitatus JW150

Myxococcus stipitatus JW150이 생산하는 세포독성 물질의 분리 및 특성

  • 안종웅 (한국화학연구원 생명의약부) ;
  • 이정옥 (한국화학연구원 생명의약부)
  • Published : 2002.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Drug resistance is one of the most significant impediments to successful chemotherapy of cancer. Multidrug-resistance (MDR) is characterized by decreased cellular sensitivity to anticancer agents due to the overexpression of P-glycoprotein. By employing a resistant subline of HCT15 to adriamycin (CL02), we undertook the screening for agents which were effective to multidrug-resistant cancer cells. As a result, a myxobacterial strain JW150 was selected for study since an activity against CL02 cells was discovered in the strain. Cytotoxicity-guided fractionation of the culture broth led to the isolation of cystothiazole A and melithiazole F. The producing organism was identified as Myxococcus stipitatus by taxonomic comparison with type strains of Myxococcus sp. as well as its morphological and physiological characteristics. Cystothiazole A and melithiazole F demonstrated potent cytotoxicity against certain human cancer cells with $IC_{50}$ values ranging from 0.03~ $0.72{\mu}{\textrm{g}}$/ml. Both compounds were interestingly as active against drug-resistant sublines CL02 and CP70 as against the corresponding parental cells.

Keywords

References

  1. Bradley, G., Juranka, P. F. and Ling, V. : Mechanism of multidrug resistance. Biochim. Biophys. Acta. 948, 87 (1988)
  2. Lum, B. L., Gosland, M. P., Kaubisch, S. and Sikic, B. I. : Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy 13, 88 (1993)
  3. Perez, R. P., Hamilton, T. C., Ozoles, R. E and Young, R. C. : Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 71, 1571 (1993)
  4. Iwahashi, T., Okochi, E., Ono, K., Sugawara, L., Tsuruo, T. and Mori, S. : Establishment of multidrug resistant human colorectal carcinoma HCT15 cell line and their properties. Anticancer Res. 11, 1309 (1991)
  5. Ueda, K., Cardarelli, G., Gottesman, M. M. and Pastan, I. : Expression of a full length eDNA for the human MDR-1 gene confers resistance to colchicine, doxorubicin, and vinblastin. Proc. Natl. Acad. Sci. USA. 84, 3004 (1987) https://doi.org/10.1073/pnas.84.9.3004
  6. Choi, S. U., Kim, N. Y., Choi, E. J., Kim, K H. and Lee, C. O. : Establishment of doxorubicin-resistant subline derived from HCT15 human colorectal cancer cells. Arch. Pharm. Res. 19, 342 (1996) https://doi.org/10.1007/BF02976376
  7. Reichenbach, H. and Dworkin, M. : The Prokaryotes 2nd ed., Springer Verlag, New York, p. 3416 (1992)
  8. Irschik, H., Jansen, R., Hoefle, G., Gerth, K and Reichenbach, H. :The corallopyronins, new inhibitors of bacterial RNA synthesis from myxobacteria. J. Antibiotics 38, 145 (1985)
  9. Yamanaka, S., Kawaguchi, A. and Komagata, K. : Isolation and identification of myxobacteria. J. Gen. Appl. Microbiol. 33, 247 (1987) https://doi.org/10.2323/jgam.33.247
  10. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon,J., Vistica, D., Warren, J., Bokesch, H., Kenny, S. and Boyd, M. R. : New colorimetric cytotoxicity assay for anticancer drug screening. J. Nat. Cancer Inst. 82, 1107 (1990) https://doi.org/10.1093/jnci/82.13.1107
  11. Gerth, K, Irschik, H., Reichenbach, H. and Trowitzsch, W. : Myxothiazol, an antibiotic from Myxococcus fulvus. J. Antibiotics 33, 1474 (1980)
  12. Nakanishi, K., Solomon, P. H. and Furutachi, N. : Infrared Absorption Spectroscopy. Nankodo, Tokyo (1981)
  13. Ojika, M., Suzuki, Y., Tsukamoto, A., Sakagami, Y., Fudou, R., Yoshimura, T. and Yamanaka S. : Cystothiazoles A and B, new bithiazole-type antibiotics from the Myxobacterium Cystobacter fuscus. J. Antibiotics 51, 275 (1998)
  14. Sasse, E, Bohlendorf, B., Hermann, M., Kunze, B., Forche, E., Steinmetz, H., Hofle, G. and Reichenbach, H. : Melithiazoles, new ${\beta}$-methoxyacrylate inhibitors of the respiratory chain isolated from Myxobacteria. J. Antibiotics 52, 721 (1999)
  15. Ahn, J.-W., Woo, S.-H., Lee, C.-O., Cho, K.-Y. and Kim, B.-S. : KRO25, a new cytotoxic compound from Myxococcus fulvus. J. Nat. Prod. 62, 495 (1999) https://doi.org/10.1021/np9804233
  16. Fudou, R., Iizuka, T. and Yamanaka S. : Haliangicin, a novel antifungal metabolite produced by a marine myxobacterium. J. Antibiotics 54, 149 (2001)